Assay development optimisation & technology

Carterra closes financing round for continued growth of the LSA platform for next generation antibody dscovery. Carterra has closed a $6M round of financing led by Ballast Point Ventures with participation from current investor, Telegraph Hill Partners. The additional funding will support the continued adoption of the innovative Carterra LSA high-throughput Surface Plasmon Resonance (HT-SPR) […]

Sphere Fluidics expands commercial operations to increase supply of Pico-Surf surfactant for droplet microfluidics. Sphere Fluidics, a company commercializing single cell analysis systems underpinned by its patented picodroplet technology, today announced investment in the production and supply of its proprietary biocompatible surfactant, Pico-Surf™, for reliable and highly stable droplet generation and processing. Sphere Fluidics will […]

State-of-the art facility is home to the company’s next-generation, fully automated platform for drug discovery. Arctoris Ltd, the developer of the world’s first fully automated drug discovery platform, today opened the doors to its new global headquarters and state-of-the-art research and development (R&D) facility in Oxford, UK. Housing the company’s proprietary technology and providing space […]

Collaborative Cancer Research UK-funded studies from University of Oxford researchers have uncovered a new mechanism by which cancer cells adapt to the stresses they encounter as they grow and respond to therapies. This mechanism involves cells releasing small vesicles, known as exosomes. These contain complex mixtures of proteins, RNAs and other molecules, which can re-programme […]

Some of the most promising advances in cancer treatment have centred on immunotherapies that rev up a patient’s immune system to attack cancer. However, immunotherapies don’t work in all patients, and researchers have been searching for ways to increase their effectiveness. Now, researchers at Washington University School of Medicine in St. Louis have combined two immunotherapy strategies […]

British Patient Capital is committing $65m to SV Health Investors’ latest fund, SV7 Impact Medicine Fund (IMF), to turn scientific breakthroughs into biotech companies producing high impact precision medicine drugs for poorly treated diseases. The commitment increases British Patient Capital’s exposure to life sciences and health technology, building on a commitment to the Dementia Discovery […]

21 July 2020 Image: Anshu A Thanks to seed financing from Boehringer Ingelheim Venture Fund (BIVF) and Evotec, Quantro Therapeutics will generate a drug discovery pipeline, aiming to transform the precision and scope of cell-based compound screens. With the introduction of ‘Transcriptional Fingerprinting’ to drug discovery, Quantro intends to revamp the scope of pharmacologic interventions […]

21 July 2020 Image: Henry Lai AbCellera has entered into an agreement with Alloy Therapeutics to use the ATX-Gx humanised mice platform to enable best-in-class in vivo human antibody discovery for its partner programs. Under the terms of the agreement, AbCellera will offer its biotech and pharma partners access to ATX-Gx, Alloy’s proprietary suite of […]

20 July 2020 Image: Toa Heftiba Sphere Fluidics and Heriot-Watt University have been awarded a Knowledge Transfer Partnership (KTP) grant from Innovate UK, the UK’s innovation agency. The grant will facilitate the development of novel droplet generator instrumentation, which will be used to expand Sphere Fluidics’ portfolio of microfluidic instruments for advanced biologics discovery and […]

Image: Fusion Medical Automation Initially designed to target the published CDC and WHO consensus sequences, the AccuPlex SARS-CoV-2 Verification Panel and Reference Material Kit are available with full SARS-CoV-2 viral genome coverage. This expansion allows for compatibility with any SARS-CoV-2 assay target, while maintaining the safety features and performance monitoring advantages of AccuPlex technology. LGC’s […]